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Commentary
Interpretation of 
Biomonitoring Data: Do 
Collection Protocols Matter?
Biomonitoring (i.e., measurement of 
  environmental chemicals, their metabolites, 
or specific reaction products in human bio-
logical specimens) to assess internal exposure 
(i.e., body burden) has increased consider-
ably in the last two decades (Needham et al. 
2007). Biological matrices are complex; some 
may be difficult to obtain and available only 
in small amounts. Moreover, environmen-
tal chemicals are normally present in the 
biological matrix at trace levels. Therefore, 
highly sensitive, specific, and selective mul-
tianalyte methods for the extraction, separa-
tion, and quantification of these chemicals 
must be developed (Needham et al. 2005). 
Undoubtedly, the adequacy of biomonitoring 
data depends strongly on reliable analytical 
measurements (Angerer et al. 2007). Even 
when the best techniques are used, they guar-
antee accurate and precise measures of the 
biomarkers levels only in any given specimen. 
However, if the integrity of the specimen was 
compromised before its analysis, the analytical 
measures, although valid, could lead to erro-
neous interpretations. Sampling, storage, and 
processing conditions have long been appreci-
ated as potential sources of contamination in 
trace analyses for metals and volatile organic 
compounds (Ashley et al. 1992; Bolann et al. 
2007; Pineau et al. 1993). Unfortunately, 
adequacy of sampling and processing meth-
ods, albeit critical for the evaluation of all 
biomonitoring data, has not received as much 
attention as the analytical techniques, espe-
cially for semivolatile organic chemicals.
Strict collection, handling, and storage 
protocols are particularly important if the 
chemicals monitored as exposure biomarkers 
are ubiquitous environmental contaminants 
or environmental degradates. Some of these 
chemicals [e.g., phthalates, polybrominated 
diphenyl ethers, polyfluoroalkyl chemicals, 
bisphenol A (BPA)] have been detected in 
indoor air and dust (Fromme et al. 2009; 
Hwang et al. 2008; Rudel and Perovich 2009; 
Volkel et al. 2008; Weschler 2009; Wilson 
et al. 2003). Therefore, care must be taken 
when collecting and processing specimens to 
be analyzed for these chemicals to ensure that 
sampling materials do not contain detectable 
levels of the target chemicals, but also that 
these materials are dust-free. Further contami-
nation with such chemicals during the analysis 
is possible. However, laboratory contamina-
tion, should it occur, would be identified and 
eliminated, provided that the laboratory per-
forming the analysis adheres to good labora-
tory practices and includes analytical/reagent 
blank samples (Taylor 1987). Therefore, the 
resulting biomarker concentrations should 
never include a contribution from contamina-
tion during laboratory analyses.
Just as reagent blanks are needed for 
assessing contamination during the analyti-
cal steps, field blanks can be used to assess 
potential contamination during sample col-
lection, storage, processing, and/or transport 
[National Institute for Occupational Safety 
and Health (NIOSH) 1994]. However, 
to further complicate matters, even if field 
blanks are used, additional information may 
be needed to determine the utility of the 
biomonitoring findings. In this article, we 
present examples that highlight the relevance 
of unforeseen and unintended contamina-
tion before laboratory analysis and its impact 
on the interpretation of biomonitoring data 
of organic chemicals. We also discuss the 
representativeness of specimens to be used 
for biomonitoring purposes. Other factors 
important for ensuring the adequate interpre-
tation of biomonitoring results, including the 
selection of the most relevant biomarkers—
based on available toxicokinetic data—for 
the chemical and population of interest; the 
potential effects of the biological matrix on 
the biomarkers’ concentrations (e.g., matrix 
enzymes and levels of some phthalate metab-
olites); and adequate storage and shipment of 
specimens (Angerer et al. 2007; Calafat and 
Needham 2008; National Research Council 
2006) are not discussed.
Potential Contamination 
during Sampling or Handling 
of Biological Specimens
For chemicals that are ubiquitous in the 
environ  ment, such as certain phthalates, care 
is needed to avoid contaminating the sam-
ples. For example, contamination of biologi-
cal specimens with di(2-ethylhexyl) phthalate 
(DEHP), a common plasticizer of polyvinyl 
chloride (PVC) and other polymers (David 
et al. 2001) used in many products, is difficult 
to avoid. In humans, DEHP metabolizes into 
its hydrolytic monoacid (commonly referred as 
“monoester”), mono(2-ethylhexyl) phthalate 
(MEHP), and then into oxidative metabo  lites 
(Figure 1) (Koch et al. 2004, 2005b, 2006; 
Silva et al. 2006). MEHP and the oxidative 
metabolites are primarily excreted in the urine 
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as phase II conjugates and much less so as the 
unchanged or free species (Dirven et al. 1993; 
Peck and Albro 1982). Measuring the urinary 
concentrations of the total (conjugated plus 
free) species of these metabolites is the most 
common biomonitoring approach for assess-
ing human exposure to DEHP (Barr et al. 
2003; Koch et al. 2003).
To evaluate the exposure to several con-
taminants, including the metabolites of DEHP 
and other phthalates, among participants of 
the Avon Longitudinal Study of Parents and 
Children (ALSPAC) (Golding et al. 2001), we 
analyzed one pooled urine sample, prepared 
from 20 individual specimens, for these con-
taminants (Holmes et al., in press). Although 
in a given urine specimen, the concentra-
tions of the total species of DEHP oxidative 
metabolites are normally higher than the total 
MEHP concentrations (Barr et al. 2003; Koch 
et al. 2003), in the ALSPAC pooled sample, 
the total urinary concentration of MEHP 
(100 µg/L) was one order of magnitude higher 
than the total concentrations of DEHP oxida-
tive metabolites mono(2-ethyl-5-hydroxyhexyl) 
phthalate (MEHHP; 13.8 µg/L) and mono(2-
ethyl-5-oxohexyl) phthalate (MEOHP; 
12.7 µg/L). Furthermore, the MEHP concen-
trations were about 25 times higher than the 
median concentrations reported for the general 
population of the U.S. National Health and 
Nutrition Examination Survey (NHANES) 
conducted during 2001–2002, but the con-
centrations of MEHHP and MEOHP were 
very similar to the concentrations reported 
for the same NHANES participants [Centers 
for Disease Control and Prevention (CDC) 
2005]. Moreover, although the DEHP 
metabolites are excreted in the urine mainly 
as glucuronides (Dirven et al. 1993; Peck and 
Albro 1982), in the ALSPAC pooled sample 
the urinary concentrations of free and total 
species of MEHP were essentially equal; for 
MEHHP and MEOHP, the fractions excreted 
as a free species were within the expected 
ranges (Kato et al. 2004). Of note, MEHP 
can also be formed from DEHP by both 
biotic and abiotic processes (Koch et al. 2006; 
Nakamiya et al. 2005; Staples et al. 1997); 
therefore, MEHP is itself an environmental 
contaminant. By contrast, no environmental 
sources of DEHP oxidative metabolites are 
known (Koch et al. 2006). These results sug-
gest that the MEHP concentrations measured 
in this pooled sample were likely the result 
of contamination with DEHP or MEHP 
during or after collection (Holmes et al., in 
press). Therefore, this MEHP concentration, 
although analytically valid, should not be used 
for exposure or risk assessment purposes. In 
addition to the higher potential for external 
contamination of MEHP compared with the 
oxidative metabolites, MEHP has a shorter 
elimination half-life and represents a smaller 
fraction of the DEHP urinary metabolites. 
Together, these results suggest that MEHP 
is a weaker biomarker of exposure to DEHP 
than the DEHP oxidative metabolites (Koch 
et al. 2006). Therefore, using only MEHP 
for exposure or risk assessment—particularly 
in archived biological samples, where external 
DEHP or MEHP contamination cannot be 
excluded—should be avoided.
Biomonitoring and Field Blanks
Sophisticated analytical chemistry techniques, 
highly trained laboratory personnel, and strict 
quality control/quality assurance laboratory 
practices define high-quality biomonitoring 
data (Angerer et al. 2007; Caudill et al. 2008; 
National Research Council 2006; Needham 
et al. 2007). Other factors, such as the integ-
rity of the specimen, are important to ensure 
the validity of biomonitoring results (National 
Research Council 2006).
In recent decades, biomonitoring initia-
tives have been implemented worldwide, 
either in support of epidemiologic investi-
gations or as part of national health surveys 
(CDC 2003; National Children’s Study 2009; 
Viso et al. 2009). Combining environmen-
tal monitoring (e.g., air, water) and exposure 
history/questionnaire data may also be used 
to assess human exposure to environmental 
chemicals and is common in occupational set-
tings (NIOSH 1994). In these scenarios, the 
collection and storage of the environmental 
specimens follow strict protocols to guarantee 
the validity and comparability of the results. 
In addition to collecting field blank and rep-
licate samples, these protocols often require 
screening of collection materials to ensure 
that they do not contain detectable levels of 
the target chemical (NIOSH 1994).
Environmental chemicals are present in 
human biological tissues at concentrations 
considerably lower than in the environment. 
Because some of these chemicals are rather 
ubiquitous in the environment, the potential 
for contamination of the biological specimen 
during sampling exists. Biomonitoring sam-
pling protocols generally include screening 
of the collection materials for potential con-
tamination, but they do not routinely include 
other provisions required for environmental 
sampling (e.g., field blanks). Commercially 
available high-purity solvents (e.g., water, 
methanol) placed in a sample container and 
processed as a specimen could serve as field 
blanks. Therefore, incorporating field blanks 
into biomonitoring programs should not be 
difficult. In addition to providing a control 
for evaluating contamination during process-
ing and storage before analysis, field blanks 
would be useful in determining whether 
archived specimens could be analyzed for a 
given chemical, even though the sampling 
materials may have not been prescreened for 
the presence of such a chemical. Therefore, we 
strongly advocate including field blanks in all 
ongoing and future biomonitoring initiatives. 
Nonetheless, although having field blanks 
Figure 1. DEHP metabolizes into its hydrolytic monoacid (“monoester”) MEHP and, after enzymatic oxi-
dation of the alkyl chain (R), to various oxidative metabolites. MEHP and the oxidative metabolites can 
be excreted in the urine unchanged or as phase II glucuronide conjugates [R = CH2CH(C2H5)(CH2)3CH3 
(MEHP); CH2CH(C2H5)(CH2)2CH(OH)CH3 (MEHHP); CH2CH(C2H5)(CH2)2COCH3 (MEOHP); CH2CH(C2H5)
(CH2)3COOH [mono(2-ethyl-5-carboxypentyl) phthalate (MECPP)].
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would strengthen all biomonitoring programs, 
the absence of field blanks does not necessar-
ily invalidate these programs’ results.
Collection of Biological 
Specimens in Medical Settings 
or after Medical Interventions
For several chemicals (e.g., mercury, DEHP, 
BPA), acute exposure can occur as a result of 
medical interventions [Barregard et al. 1995; 
Calafat et al. 2004, 2009; Food and Drug 
Administration (FDA) 2001; Koch et al. 
2005a]. However, many sources of exposure 
to such chemicals, especially those that are 
not considered “active” in a given product, are 
unknown. The following example illustrates 
the potential impact on interpreting biomoni-
toring results when the biological specimens 
are collected in medical settings. More impor-
tant, this example highlights the need for 
additional research to identify all sources and 
pathways of human exposure to these chemi-
cals, particularly for those used extensively and 
suspected to affect human health.
One hundred fifty pregnant women 
partici  pating in a prospective study of pes-
ticides and other endocrine disruptors in 
maternal and fetal compartments were put 
on intra  venous injection for glucose, water, 
and electrolyte balance support upon arrival 
at a hospital for a scheduled cesarean birth. 
Maternal urine specimens, collected before 
delivery but after a Foley tube and the intra-
venous line were placed, were analyzed for 
phthalate metabolites (Yan et al. 2009). 
Among these women, the urinary concentra-
tions of most metabolites were similar to or 
lower than those among the U.S. general pop-
ulation from NHANES 2001–2002 (CDC 
2005). However, the median urinary con-
centrations of the DEHP oxidative metabo-
lites MEHHP (108.9 µg/L) and MEOHP 
(95.1 µg/L) were more than 5 times their 
corresponding NHANES concentrations; for 
MEHP, the median (114.7 µg/L) was more 
than 20 times higher. DEHP, approved by 
the FDA for medical uses (FDA 2001), is a 
plasticizer in PVC plastics, which can be used 
in medical tubing and blood storage bags. 
Therefore, the higher-than-population-based 
urinary concentrations of DEHP metabolites 
among these women likely reflect their expo-
sures to DEHP in the hospital. This example 
further illustrates the limitations of MEHP 
as exposure biomarker because the collection 
of the urine (directly in a cup or through the 
Foley tube into a bag) could affect the MEHP 
urinary concentrations, because DEHP/
MEHP may leach from some of these mate-
rials, as well as from the intravenous line. In 
contrast, the concentrations of the oxidative 
metabolites, which cannot be formed except 
through enzymatic processes, would reflect 
these women’s acute DEHP exposure, thus 
confirming the validity of the DEHP oxida-
tive metabolites as exposure biomarkers (Koch 
et al. 2006).
This example also emphasizes that 
biomonitoring for chemicals that are widely 
used in consumer and personal care prod-
ucts (e.g., phthalates, BPA, parabens) requires 
additional considerations beyond choosing 
optimal exposure biomarkers and analytical 
methods. Even if sampling materials are pre-
screened and known to be contaminant-free, 
and field blanks are collected, the study design 
itself, specifically the timing and mode of col-
lecting the biological samples, may involve 
the use of materials or products that contain 
the target compounds (or their precursors) 
(National Toxicology Program 2008). In 
the example above, the concentrations of the 
DEHP metabolites, although accurate and 
reflective of a real exposure to DEHP at the 
time of delivery, cannot be used as surrogates 
for DEHP exposure throughout gestation or 
even for exposures of the general population.
Representativeness of the 
Biological Specimen
Biological samples are complex in nature. 
Because some may be difficult to obtain and 
may be available only in small amounts, rig-
orous protocols for collecting these samples 
are needed. In addition, it is crucial that 
the specimens used for biomonitoring truly 
reflect the composition of the original sample. 
Maintaining a sample’s representativeness starts 
when separating samples into specimens, gen-
erally performed to reduce repeated thaw/freeze 
cycles, thus minimizing potential contami-
nation and degradation (National Research 
Council 2006). The sample must be fully 
thawed (if frozen before) and mixed before 
making aliquots, and care must be taken to 
ensure the correct labeling of each specimen.
Further, the concept of representativeness 
may be of particular interest in the case of 
samples collected from infants, young chil-
dren, and pregnant women and in situations 
where cross-contamination of the specimen 
with other tissues/fluids can occur. For exam-
ple, urine collected from a woman during 
her period could be tainted with blood, and 
contamination of seminal fluid with urine 
cannot be ruled out. In these situations, we 
recommend that the potential for contamina-
tion be noted. Furthermore, guidance for the 
collection of samples to minimize potential 
cross-matrix contamination in such situations 
is needed. Amniotic fluid, cord blood, and 
meconium are promising matrices for assessing 
prenatal exposures, a period when humans are 
highly susceptible to potential adverse health 
effects from exposure to certain chemicals. If 
cross-contamination of the specimen occurs, 
biomarkers measured in meconium and in 
amniotic fluid would reflect exposure not only 
during gestation but also during the neo  natal 
period or during delivery, particularly for 
ubiquitous chemicals or those commonly pres-
ent in medical settings. Therefore, it is critical 
that the personnel responsible for collecting 
the samples appropriately document all events 
related to the collection and communicate 
them to the study principal investigator and 
the analytical laboratory personnel.
Cross-contamination of amniotic fluid 
with the mother’s blood during delivery might 
affect primarily the amniotic fluid concentra-
tions of persistent chemicals that are normally 
measured in blood or serum/plasma. By con-
trast, cross-contamination of meconium or 
another matrix with urine would likely have 
a bigger impact for nonpersistent chemicals, 
which are metabolized and eliminated primar-
ily in the urine, than for persistent chemicals 
that undergo rather limited urinary excretion. 
To minimize the potential impact of cross-
contamination of meconium/feces with urine, 
additional measures for standardizing the col-
lection procedures, such as avoiding the use of 
diapers containing meconium/feces that also 
appear to be wet, can be implemented (Calafat 
and Needham 2008). Although measuring 
chemicals in complex biological matrices is 
analytically possible (Needham et al. 2005), 
because of potential uncertainties during col-
lection, interpreting the concentrations of 
biomarkers in matrices with relatively high 
potential for cross-contamination should be 
conducted cautiously.
One other consideration that may affect 
the representativeness of a given sample relates 
to the collection of urine by using absorbent 
materials (e.g., diapers). First, one must ensure 
that these materials do not contain the tar-
get chemical. Second, unlike urine collected 
directly in a urine cup, bag, or similar con-
tainer, these specimens need to be extracted 
from the absorbent material before their analy-
ses (Lee and Arbuckle 2009). As expected, 
the urine, other urinary biomolecules or sol-
utes, and both conjugated and free urinary 
species of the target chemicals will be only 
partially recovered, and the composition of 
the extracted urine will change. The extraction 
efficiency of a given compound relates to its 
aqueous solubility, which strongly depends on 
its chemical structure—which determines its 
physicochemical properties (e.g., lipophilic-
ity, ionizability)—and on the nature of the 
solution (i.e., urine), which is affected by pH, 
ionic strength, temperature, and other solutes 
(Kerns et al. 2008).
In general, the recovery from absorbent 
materials of the urinary conjugates of a chem-
ical will be higher than that of the less hydro-
philic free species. Because organic chemicals 
are excreted mostly as urinary conjugates, 
interpretation of biomonitoring results should 
not be affected considerably provided an Calafat and Needham
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adequate extraction of the conjugates exists. 
Nonetheless, because of the differential extrac-
tion losses, exposures to organic chemicals, 
if estimated from the concentrations of free 
and conjugated (i.e., total) species in urine 
collected from absorbent materials, may 
be somewhat underestimated, whereas the 
fraction of the chemicals excreted as conju-
gates may be overestimated. Therefore, urine 
sampling methods from infants and young 
children (Lee and Arbuckle 2009) should be 
examined for their potential impact in the 
exposure assessment process. Other methods 
that do not require using absorbent materials 
should be evaluated.
Recommendations for Best 
Biomonitoring Practices
Adequate generation of biomonitoring data 
requires validated and high-quality analyti-
cal methods, qualified laboratory personnel, 
and strict quality control/quality assurance 
laboratory practices. Other important aspects 
include the selection of the most relevant bio-
markers and understanding of the potential 
effects of the biological matrix on the bio-
markers’ concentrations. Furthermore, other 
factors, including adequate collection, han-
dling, shipping, and storage procedures to 
preserve the integrity of the specimen and the 
target analytes, must be considered to guar-
antee the valid interpretation of the biomoni-
toring data, particularly for chemicals with 
widespread commercial and industrial use.
Recommendations for sampling and pro-
cessing approaches applicable to ongoing and 
future biomonitoring initiatives include the 
following:
•	Inclusion	of	field	blank	samples	(e.g.,	high-
purity solvent(s) placed in a sample container 
and processed as a biological specimen) in 
the protocols for the collection and/or 
processing of biological specimens for all 
programs/  studies with a current or potential 
biomonitoring component.
•	To	the	fullest	extent	possible,	evaluation	
a priori of the potential impact of the col-
lection setting on the biomonitoring con-
centrations (especially of chemicals that may 
be present in commonly used products). 
Available data suggest that the main issues 
relate to collecting biological samples from 
pregnant women at the time of delivery (e.g., 
use of intra  venous line) or from persons 
undergoing intensive care and/or outpatient 
medical treatment (e.g., platelet donation, 
dialysis). Therefore, additional research is 
needed to identify all sources and pathways 
of human exposure to these widely used 
chemicals, many of which are not considered 
“active” ingredients in commercial products.
•	Recording	of	the	parameters	related	to	col-
lecting and processing of samples. This 
includes information on the sampling time 
and location (e.g., home, hospital, work-
place), whether sampling was embedded into 
prescheduled or ad hoc health visits (e.g., 
child well-being, prenatal care appointments, 
amniocentesis, delivery), and detailed descrip-
tion of collection procedures (e.g., urine 
collected in a cup or diaper, or through a 
catheter) and of the processing (e.g., making 
aliquots, storage and shipping conditions) of 
the samples before arrival to the laboratory 
for analysis.
•	Evaluation	of	the	sampling	collection	proto-
cols to identify the potential for cross-matrix 
contamination (e.g., urine or amniotic fluid 
with blood, meconium/feces, or seminal 
fluid with urine).
•	Consideration	of	the	extraction	efficiency	
of urinary species of chemicals from diapers 
when interpreting biomonitoring data from 
infants and young children. It is possible 
that the conjugation capability, assessed 
from the percentage of conjugated species, 
would be somewhat overestimated. By con-
trast, exposure, categorized from the urinary 
concentrations of the total (free plus conju-
gated) species, would be underestimated.
•	Examination	of	the	methods	for	collect-
ing urine from infants and young children 
for their potential impact on the exposure 
assessment process (e.g., changes in the com-
position of urine extracted from a diaper), 
and evaluation of collection methods not 
relying on the use of absorbent materials for 
their applicability in biomonitoring studies.
Biomonitoring requires a team approach. 
Therefore, it is critical to facilitate constructive 
dialog and partnership among laboratory and 
field researchers and study participants from 
the onset of the study to ensure its success.
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